巴曲酶对急性脑梗死患者血浆溶血磷脂酸水平的影响

Influence of Batroxobin on plasma level of lysophosphatidic acid in patients with acute cerebral infarction

目的研究巴曲酶对急性脑梗死患者血浆溶血磷脂酸(LPA)水平的影响。方法61例急性脑梗死患者随机分为巴曲酶组(31例)和常规治疗组(30例),两组均给予阿司匹林、丹参注射液治疗;巴曲酶组加用巴曲酶治疗1个疗程。检测两组患者治疗前、治疗后5d、7d、10d和14d的血浆LPA浓度,并与健康体检者(正常对照组)比较。结果两急性脑梗死组治疗前血浆LPA水平显著高于正常对照组(均P<0·001);治疗后血浆LPA水平逐渐降低,巴曲酶组于治疗后10d、常规治疗组于治疗后14d与正常对照组相比差异无显著性(均P>0·05);巴曲酶组治疗后5d、7d、10d血浆LPA水平显著低于常规治疗组(均P<0·001),恢复正常亦早。结论巴曲酶能显著降低急性脑梗死患者的血浆LPA水平,抑制血小板聚集。

Objective To investigate the influence of Batroxobin on plasma level of lysophosphatldic acid （LPA） in patients with acute cerebral infarction. Methods A total of 61 patients with acute cerebral infarction were selected randomly to Batroxobin group （ n = 31 ） or control group （ n = 30）. Aspirin and Danshen root were used in both groups as basic treatment. Batroxobin was used in Batroxobin group for one course of treatment. The plasma levels of LPA were measured before treatment and 5th, 7th, 10th, and 14th day after treatment in both acute cerebral infraction groups, and compared with health volunteers（normal group）. Results The plasma levels of LPA in both Batroxobin group and control group were remarkably higher than that in normal group（ all P 〈0. 001 ） and gradually decreased after treatment. There was no significant difference of plasma levels of LPA between normal group and Batroxobin group at 10 d or control group at 14 d after treatment（ all P 〉 0. 05 ）. In Batroxobin group the plasma levels of LPA were significantly lower than that in control group at 5th, 7th, 10th, 14th day after treatment（ all P 〈 0. 001 ） and returned to normal earlier. Conclusions Batroxobin can significantly decrease the plasma level of LPA and inhibit platelet aggregation in patients with acute cerebral infarction.